Reporting from the 2021 Genitourinary Cancers Symposium, Matthew Galsky features practice changing results from Urothelial Carcinoma studies testing adjuvant nivolumab after radical surgery in muscle-invasive disease with high risk for relapse, and evaluating enfortumab vedotin vs standard chemotherapy in patients with previously treated advanced disease.
Abstracts:
- Abstract 391: First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC), Dean Bajorin
- Abstract 393: Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma, Thomas Powles
This video was supported with an educational grant from Janssen Oncology